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Abstract: 
Tissue engineered oral mucosal equivalents (OME) are being increasingly 
used to measure toxicity, drug delivery, and to model oral diseases. 
Current OME are mainly comprised of normal oral keratinocytes (NOK) 
cultured on top of a normal oral fibroblasts (NOF)containing matrix. 
However, the commercial supply of NOK is limited, restricting widespread 
use of these mucosal models. In addition, NOK suffer from poor longevity 
and donortodonor variability.  Therefore, we constructed, characterised 
and tested the functionality of oral mucosal equivalents based on 
commercial TERT2immortalised oral keratinocytes (FNB6) in order to 
produce a more readily available alternative to NOKbased OME. FNB6 OME 
cultured at an airtoliquid interface for 14 days exhibited expression of 
differentiation markers cytokeratin 13 in the suprabasal layers and 
cytokeratin 14 in basal layer of the epithelium. Proliferating cells were 
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restricted to the basal epithelium and there was immunopositive 
expression of Ecadherin confirming the presence of established celltocell 
contacts. The histology and expression of these structural markers 
paralleled those observed in the normal oral mucosa and NOKbased 
models. Upon stimulation with TNFα & IL1, FNB6 OME displayed a similar 
global gene expression profile to NOKbased OME with increased 
expression of many common proinflammatory molecules such as 
chemokines (CXCL8), cytokines (IL6) and adhesion molecules (ICAM1) 
when analysed by gene array and qPCR. Similarly, pathway analysis 
showed that both FNB6 and NOK models initiated similar intracellular 
signalling upon stimulation. Gene expression in FNB6 OME was more 
consistent than NOKbased OME that suffered from donor variation in 
response to stimuli. Mucosal equivalents based on immortalised FNB6 cells 
are accessible, reproducible and will provide an alternative animal 
experimental system for studying mucosal drug delivery systems, host
pathogen interactions and druginduced toxicity.   
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Abstract  
Tissue engineered oral mucosal equivalents (OME) are being increasingly used to measure 
toxicity, drug delivery, and to model oral diseases. Current OME are mainly comprised of 
normal oral keratinocytes (NOK) cultured on top of a normal oral fibroblasts (NOF)-
containing matrix. However, the commercial supply of NOK is limited, restricting widespread 
use of these mucosal models. In addition, NOK suffer from poor longevity and donor-to-
donor variability.  Therefore, we constructed, characterised and tested the functionality of 
oral mucosal equivalents based on commercial TERT2-immortalised oral keratinocytes 
(FNB6) in order to produce a more readily available alternative to NOK-based OME. FNB6 
OME cultured at an air-to-liquid interface for 14 days exhibited expression of differentiation 
markers cytokeratin 13 in the suprabasal layers and cytokeratin 14 in basal layer of the 
epithelium. Proliferating cells were restricted to the basal epithelium and there was 
immuno-positive expression of E-cadherin confirming the presence of established cell-to-
cell contacts. The histology and expression of these structural markers paralleled those 
observed in the normal oral mucosa and NOK-based models. Upon stimulation with TNFα & 
IL-1, FNB6 OME displayed a similar global gene expression profile to NOK-based OME with 
increased expression of many common pro-inflammatory molecules such as chemokines 
(CXCL8), cytokines (IL-6) and adhesion molecules (ICAM-1) when analysed by gene array and 
qPCR. Similarly, pathway analysis showed that both FNB6 and NOK models initiated similar 
intracellular signalling upon stimulation. Gene expression in FNB6 OME was more consistent 
than NOK-based OME that suffered from donor variation in response to stimuli. Mucosal 
equivalents based on immortalised FNB6 cells are accessible, reproducible and will provide 
an alternative animal experimental system for studying mucosal drug delivery systems, host-
pathogen interactions and drug-induced toxicity.   
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Introduction 
The use of three-dimensional models of human tissue has come to the forefront of medical 
research in recent years and has shown to be a powerful tool in both industry and academia 
for the testing of drug responses and tissue toxicity (1). Physiologically relevant 3D models 
are rapidly becoming the preferred experimental in vitro model because cells cultured as 
monolayers do not represent the complex tissue microenvironment present in living 
organisms and often prove to be poor predictors drug-induced cell toxicity (2, 3). Moreover, 
increased awareness the desire to replace, refine or reduce animals in experimental 
procedures where possible of the three R’s has prompted a move away from in vivo 
research to in vitro assays in many areas of science. This is especially true for epithelial 
biology in response to the Organisation for Economic Co-operation and Development 
(OECD) guidelines and European Commission regulation (440/2008/EC) unequivocally 
promoting the use of validated, tissue engineered in vitro human epidermal models as 
alternative models for skin/eye irritation (No.439), sensitisation (No.442D) and corrosion 
tests (No.431; OECD (2013)). Oral mucosal equivalents (OME) are also being increasingly 
used in a wider range of scientific research including host-pathogen interactions (4, 5), 
xenobiotic enzyme metabolism (6, 7), cancer biology (8, 9)  and biomaterial compatibility 
(10, 11). Currently, most OME are based on the co-culture of primary normal oral 
keratinocytes (NOK) on top of a hydrogel matrix containing normal oral fibroblast (NOF) 
cultured at an air-to-liquid interface (12, 13). However, in some instances OME based on the 
use of malignant keratinocytes to replace NOK have been used to model the oral mucosa 
(14, 15). The paracrine interactions between the NOF and NOK are essential for the growth 
and differentiation of the keratinocytes to produce a multilayer, stratified squamous 
epithelium (16).  Although the physiological and histological structure of the oral mucosa is 
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very similar to that of the skin, there are key differences. Similar to skin the oral epithelium 
is comprised of basal cells that are attached to the connective tissue basement membrane 
via hemidesmosome contacts. As the basal cells divide and migrate apically into the 
suprabasal spinous layer they undergo continuous alterations in gene expression and 
morphology that eventually differentiate into cells that make up the granular layer, which 
constitutes the main permeability barrier of the epithelium. In some anatomical parts of the 
oral mucosa such as the hard palate, these cells then differentiate further into a highly 
keratinised, cornified layer similar to the skin, but in other areas such as the buccal mucosa 
or lingual regions the mucosa is non-keratinised. The basal cells express keratin 5/14 whilst, 
in contrast to the skin, the suprabasal cells express keratin 4/13 in addition to late 
epidermal differentiation proteins involucrin and flaggarin. OME based on primary cells 
have shown that these models express all of the structural and histological characteristics as 
normal tissue and are excellent substitute models for native tissue (8, 17, 18). However, 
there are several disadvantages with constructing OME using primary keratinocytes. These 
include the dependency on the supply of isolated keratinocytes form surgically extracted 
donor oral tissue, the inherent donor-to-donor variation from one batch of keratinocytes to 
another and the restricted proliferation capacity of these cells.  To compound these issues 
and in contrast to skin keratinocytes, the commercial supply of oral keratinocytes is severely 
restricted. Therefore, there is a need to generate OME based on immortalised keratinocytes 
to enable more widespread access to OME and to reduce donor variation. Normal oral 
keratinocytes have been immortalized by over-expression of hTERT using stable transfection 
(13), the consequence of which prevents telomere shortening thereby increasing the life-
span and proliferative capacity of cells whilst maintaining their phenotype (19).   
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In this study we examined whether FNB6 TERT-immortalised oral keratinocytes are a 
suitable cellular source to construct a fully differentiated stratified squamous epithelium 
that is phenotypically and histologically similar to normal oral mucosa and OME based on 
NOK. In addition, the innate immune functionality of the epithelium was tested against 
NOK-based models based on their gene and protein expression responses to pro-
inflammatory cytokines and bacterial lipopolysaccharide to mimic oral inflammation.  
 
Materials and methods 
Cell culture of primary cells, immortalized oral keratinocytes and oral cancer cells 
FNB6-TERT immortalised oral  keratinocytes (Beatson Institute for Cancer Research, 
Glasgow, UK; commercially available at Ximbio, London, UK) originally isolated from the 
buccal mucosa (20) and H357, an oral squamous cell carcinoma cell line derived from the 
tongue (21) (Health Protection Agency Culture Collections, Salisbury, UK) were cultured in 
Green’s Medium consisting of Dulbecco’s Modified Eagle’s Medium (DMEM) and Ham’s F12 
medium in a 3:1 (v/v) ratio supplemented with 10% (v/v) foetal calf serum (FCS), 0.1 μM 
cholera toxin, 10 ng/ml epidermal growth factor, 0.4 μg/ml hydrocortisone, 0.18 mM 
adenine, 5 μg/ml insulin, 5 μg/ml transferrin, 2 mM glutamine, 0.2 μM triiodothyronine, 
0.625 μg/ml amphotericin B, 100 IU/ml penicillin and 100 μg/ml streptomycin. Normal oral 
fibroblasts were isolated from the connective tissue of biopsies obtained from the buccal 
and gingival oral mucosa from patients during routine dental procedures with written, 
informed consent (ethical approval number 09/H1308/66) as previously described (8) and 
cultured in DMEM supplemented with 10% FCS, 2 mM glutamine, 100 IU/ml penicillin and 
100 μg/ml streptomycin.  
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Oral mucosal equivalent  
Oral mucosal models were constructed as previously described (22). Briefly, freeze dried rat-
tail collagen was dissolved in 0.1 M acetic acid to give a final concentration of 5 mg/ml and 
stored at 4
o
C until use.  FBS, 10 x DMEM, L-Glutamine and reconstitution buffer (2.2% 
sodium bicarbonate, 4.8% HEPES, 0.248% NaOH in dH20) were added to the collagen and pH 
adjusted to 7.4. Gingival NOF were added to the collagen mixture at a concentration of 2.5 x 
10
5
 cells/ml before adding 1 ml to 12 mm cell culture transwell inserts (0.4 μm pore, 
Millipore) and allowed to set in a humidified atmosphere at 37
o
C for 2 h. Inserts were 
submerged in media and incubated for 2 d, after which 5 x 10
5
 oral keratinocytes (H357 or 
FNB6) per model were seeded on to the surface. After a further 2 d, the models were raised 
to an air-to-liquid interface and cultured for 14 d. ORL-300-FT buccal full-thickness OME 
based on buccal-derived NOK cultured on top of a gingival fibroblast-populated collagen 
hydrogel scaffold were purchased from MatTek Corp., (Ashland, MA, USA) and used 
according to the manufactures instructions. 
 
Stimulation of OME  
OME were stimulated by placing 50 μl of 20 ng/ml TNFα + 10 ng/ml IL-1β or 100 ng/ml LPS 
(E. coli serotype O55:B5, Sigma, Poole, UK) on top of the models and incubating for 6 or 24 h 
in a humidified atmosphere at 37°C. Unstimulated controls consisted of OME incubated with 
medium alone.  
 
Histological analysis 
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For histological analysis, OME were removed from the culture medium, washed with PBS 
and fixed in 10% buffered formalin overnight. The entire model (connective tissue and 
epithelium) were removed from the transwell insert along with the polycarbonate filter and 
subjected to routine histological processing and then paraffin wax embedded. Five μm 
sections were cut using a Leica RM2235 microtome (Leica microsystems) and stained with 
Haematoxylin and eosin (H&E) or subject to immunohistochemistry (IHC). Formalin fixed 
paraffin embedded normal oral mucosal tissue was used as a control for histological and 
immunohistochemical analysis, ethical approval was granted by the Sheffield Research 
Ethics Committee (Ref: 07/H1309/105).                                                            
 
Immunohistochemical analysis 
Sections were dewaxed, rehydrated through a series of alcohol dilutions and endogenous 
peroxidase neutralised with 3% hydrogen peroxide in methanol for 20 minutes. Antigen 
retrieval was achieved using 0.01 M Tri sodium citrate buffer (pH 6) at high temperature. 
Following blocking with normal goat serum for 20 minutes at room temperature sections 
were incubated with primary antibody (Table 1) or IgG iso ype control antibody for 1 h at 
room temperature. Secondary antibody and avidin-biotin complex (ABC) provided with 
Vectastain Elite ABC kit (Vector labs, Peterborough, UK) were used in accordance with the 
manufacturer’s instructions. Finally, 3’-diaminobenzidine tetrahydrochloride (DAB; Vector 
labs, Peterborough, UK) was used to visualise peroxidase activity and the sections 
counterstained with haematoxylin, dehydrated and mounted in DPX. Light microscope 
images were taken using an Olympus BX51 microscope and Colour view IIIu camera with 
associated Cell^D software (Olympus soft imaging solutions, GmbH, Münster, Germany). 
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Lactate Dehydrogenase (LDH) release assay  
Cell damage was analysed by measuring the release of LDH into the culture medium using a 
CytoTox96 enzyme assay kit as described in the manufacturer’s instructions (Promega, 
Southampton, UK). Briefly, 50 μl of conditioned culture medium from cell cultures was 
added to 50 μl of reconstituted substrate mix in a well of a 96-well flat-bottomed plate. The 
plate was incubated for 30 minutes at room temperature before stopping the reaction using 
50 μl acetic acid and the absorbance measured at 492 nm.  
 
Quantitative Real-Time PCR (qRT-PCR)  
Total RNA was extracted from cells using Isolate II RNA kit (Bioline, London, UK). 500 ng of 
total RNA was reverse transcribed using High Capacity RNA to cDNA kit (Life Technologies, 
Paisley, UK) cDNA (0.5 μl) was amplified with 5 μl 2X TaqMan gene expression master mix, 
0.5 μl Taq-Man pre-designed gene probes and 3.5 μl nuclease-free water, using an Applied 
Biosystems Real-Time PCR System. The human TaqMan gene expression probes used were 
CXCL8 (hs00174103_m1) and Intercellular adhesion molecule-1 (ICAM-1) (hs00164932_m1). 
β-2-microglobulin (hs00187842_m1) was used as the reference control gene (all Applied 
Biosystems). Real-time PCR cycles were: 95°C for 10 minutes followed by 40 cycles of 15 
seconds at 95°C followed by 1 minute at 60°C. Real-Time PCR were analysed in 3 
independent experiments. The threshold cycle (Ct) was normalised against the reference 
gene (ΔCt) and then fold changes in expression relative to untreated groups calculated using 
the formula 2
-ΔΔCt
.  
 
Enzyme-linked immunosorbent assay 
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Commercially available ELISA (OptEIA™, BD Bioscience) kits were used according to the 
manufacturer’s instructions to measure levels of CXCL8 and IL-6 in tissue culture 
conditioned medium of OME as described previously (4). 
 
Gene Array  
Linear amplification of RNA was performed using GeneChip® 3' IVT Express Kit (Affymetrix, 
Santa Clara, CA, USA) following the manufacturer’s instructions. Briefly, 200 ng mRNA was 
reverse transcribed using an oligo(dT) primer and then converted to double-stranded cDNA 
containing a T7 polymerase promoter site. Antisense RNA containing biotinylated dUTPs 
was generated by T7 promoter-driven linear amplification for 16 hours at 40°C. 15 μg of the 
antisense RNA was fragmented in Fragmentation Buffer at 94°C for 30 minutes. One μl of 
fragmented antisense RNA was assessed using an RNA 6000 Nano Chip on a 2100 
Bioanalyzer (Agilent Technologies, Santa Clara, CA). Hybridisation was carried out following 
using the instructions in the GeneChip® Hybridization, Wash, and Stain Kit (Affymetrix, Santa 
Clara, CA). Briefly 12.5 μg of fragmented antisense RNA was included in a cocktail that also 
contained serial concentrations of pre-labelled hybridization controls (bioB, bioC, bioD, and 
cre genes) and positive oligonucleotide B2 control (B2 oligo). After 16 hours hybridisation at 
42°C with rotation at 60 rpm, the GeneChips were washed and stained in a GeneChip 
Fluidics Station 450 (Affymetrix) following the protocol EukGE-WS2v5_450 as described in 
the manufacturer’s manual, and scanning was performed using a GeneChip Scanner 3000 
7G (Affymetrix). Following scanning, image files (.CEL) were processed using the Expression 
Console Software (Affymetrix) in order to carry our quality control and to prepare an RMA 
normalised dataset of the signal intensity for each probe set. Differential gene expression 
was determined using the Qlucore ‘omics Explorer Package (Qlucore, Lund, Sweden).  
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Statistics 
Data are presented as mean values ± standard deviation (SD) of three independent 
experiments (n=3) with each test performed in triplicate unless otherwise stated. ANOVA 
multiple statistical comparisons were performed using GraphPad Prism v6.00 (GraphPad 
Software, La Jolla, CA, USA) and differences between test and control groups were 
considered significant when p < 0.05. 
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Results 
OME constructed of human FNB6 TERT-immortalised oral keratinocytes resembles native 
skin and NOK-based OME.  
Full-thickness, tissue-engineered oral mucosa was generated using either immortalised 
buccal keratinocytes (FNB6) or the OSCC cell line (H357) and the morphology, differentiation 
and proliferation status of these models compared to commercially available NOK-based 
OME or healthy, normal oral mucosa. Histological analysis showed that OME generated 
using FNB6 immortalised oral keratinocytes produced a multi-layered well-defined, 
stratified epithelium approximately 120 μm in thickness with ki-67 positive proliferating 
cells restricted to the basal keratinocytes (Fig. 1 A&B). The epithelium of FNB6-based OME 
was stratified, non-keratinised and differentiated with the stratum spinosum and stratum 
granulosum layers immune-positive for cytokeratin 13. In addition, these OME displayed 
immuno-reactive staining for E-cadherin showing the presence of well-defined cell-to-cell 
contacts (Fig. 1 C-E). The histology and expression of these markers was generally 
comparable to those seen in both the NOK-based OME and particularly the normal oral 
buccal mucosa (Fig. 1 A-E). Interestingly, both FNB6 OME and NOK-based OME displayed 
cytokeratin 14 expression throughout the entire epithelium whereas in normal oral mucosa 
this was mainly restricted to the basal epithelial cells. In stark contrast, OME generated 
using the OSCC cell line H357 produced a multi-layered but non-stratified epithelium with 
ki67-positive proliferating cells throughout the stratum spinosum and stratum granulosum, 
and not restricted to the basal layer (Fig. 1).  Although E-cadherin staining was positive and 
extensive confirming cell-to-cell contacts, cytokeratin 13 and 14 expression was abnormal 
with immune-positive staining observed throughout the epithelium showing aberrant of 
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keratinocyte differentiation. Desquamation of Keratinocytes from the surface of the 
epithelium was observed for both NOK and FNB6 OME but not for H357 models.  
Furthermore, in contrast to models based on NOK and FNB6 cells, H357 mucosal models 
displayed frequent evidence of epithelial invasion into the underlying collagen scaffold (Fig. 
1). 
 
FNB6 TERT-immortalised OME is functionally responsive to pro-inflammatory cytokine 
stimulation. 
Previously, we have shown that OME can be used to study gene and cytokine responses in 
response to cytokine and microbial insult (14, 22). To investigate the innate immune 
response of the OME epithelium, FNB6, H357 and NOK-based OME were treated with a 
combination of TNFα and IL-1β or LPS and the epithelium RNA and conditioned medium 
generated from the entire OME was analysed for chemokine (CXCL8) and adhesion molecule 
(ICAM-1) gene expression and cytokine secretion (CXCL8, IL6) respectively.  Treatment with 
cytokines or LPS had no effect on the morphology of any of the OME nor did these 
inflammatory mediators cause any statistically significan  difference in release of LDH 
compared to un-stimulated controls (data not shown). Treatment with TNFα + IL-1β caused 
a statistically significant increase (p<0.05) in the gene expression of CXCL8 (10-fold) and 
ICAM-1 (4-fold) in FNB6 OME compared to controls (Fig. 2A & B) and this trend was 
mirrored in both NOK-based and H357 OME where gene expression of CXCL8 was increased 
4-fold for both NOK and H357 OME and 10-fold for ICAM-1 (NOK OME) and 4-fold for H357 
OME, respectively, compared to unstimulated controls in all cases; Fig. 2A-F). Stimulation 
with LPS did not statistically significantly (p>0.5) increase the gene expression of CXCL8 or 
ICAM-1 in any of the OME although expression of CXCL8 was consistently raised in NOK-
Page 15 of 37
Mary Ann Liebert, Inc.,140 Huguenot Street, New Rochelle, NY 10801
Tissue Engineering
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review ONLY/ Not for Distribution 15
based OME compared to controls (Fig. 2A-F). In addition, pro-inflammatory cytokine 
stimulation resulted in a statistically significant (p<0.05) increase in CXCL8 secretion in FNB6 
and H357 OME, with these showing a 6-fold increase in concentration compared to 
untreated controls (Fig. 3). FNB6 OME showed no statistically significant (p>0.05) increase in 
CXCL8 secretion in response to LPS compared to control, whereas H357 models showed a 5-
fold increase in CXCL8 secretion compared to untreated controls (Fig 3.). Surprisingly, NOK 
OME showed no statistically significant increase in secreted CXCL8 in response to LPS or 
TNFα and IL-1β treatment (Fig. 3).  
 
FNB6 TERT-immortalised OME has a similar pro-inflammatory gene profile to NOK-based 
OME. 
Since FNB6 OME were structurally and histologically similar to NOK OME and that both OME 
responded to cytokine stimulation by release of CXCL8 and ICAM-1, we wanted to 
determine if this similarity in epithelial gene expression was extended at a global scale. 
Therefore, gene expression of cytokine or LPS stimulated FNB6 and NOK epithelium were 
subjected to microarray analysis and compared to unstimulated controls.  Hierarchical gene 
cluster analysis showed that gene expression in unstimulated cells was similar for NOK and 
FNB6 models with OME producing a similar global gene expression profile (Fig. 4A). 
Moreover, at a global scale both NOK-based and FNB6 OME displayed similar gene profiles 
when stimulated with cytokines with responses being indistinguishable on hierarchical 
analysis between the two models (Fig. 4A). In contrast, the global pattern of gene 
expression of the two models in response to LPS stimulation was un-clustered showing 
desperate patterns between models (Fig. 4A).    
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Additional principal component analyses confirmed these finding and showed that the 
overall gene responses of FNB6 and NOK OME clustered together when these models were 
unstimulated or stimulated with cytokines, LPS or (Fig. 4B).  The top 10 up-regulated genes 
for cytokine stimulated FNB6 and NOK OME are shown in Tables 2 & 3. Overall, the genes 
up-regulated by cytokine treatment in both FNB6 and NOK OME are pro-inflammatory in 
nature and include IL-6, pentraxin-related protein-3 (PTX3), prostaglandin-endoperoxide 
synthase-2 (PTGS2), Tumor Necrosis Factor-inducible gene 6 protein (TNFA1P6) and an array 
chemokines. Moreover, signal transduction pathway data analysis from the gene data of 
both FNB6 and NOK OME show that activation of the NFκB signaling pathway is common to 
both cytokine treated OME with key regulatory factors such as IKKγ, IκBα being affected. In 
addition, other pro-inflammatory pathways were commonly activated such as MAPK, JNK 
and MEK1/2 (Fig. 5A).  The mean global expression data was then broken down into 
expression data from each individual experiment to examine the inter-experimental 
variability between different batches of OME and to determine if NOK models are subjected 
to donor variability.  Figure 5B shows that OME generated from FNB6 models cluster 
together suggesting a similar global gene response pattern between experiments and 
provide evidence of good inter-experimental variability. In contrast, the global expression 
gene expression profiles of NOK OME were statistically significantly (p<0.05) different with 
one NOK OME showing a distinct cluster pattern compared to the other NOK OME (Fig. 5B).  
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Discussion  
Advances in tissue culture technology and the commercial availability of NOK-based OME 
has led to a dramatic increase in their use both in industry and academia, and it is now 
generally accepted that use of 3D tissue models provides more robust data compared to 2D 
counterpart (23). However, there are drawbacks and the lack of availability and inherent 
donor-to-donor variability of oral keratinocytes, and the financial cost of purchasing 
commercially available OME have hindered the universal use of these model systems. To 
circumvent these issues some investigators have turned to using OME based on oral cancer 
cells to mimic the oral mucosa (14). Previous studies have employed TERT-immortalised oral 
keratinocytes (OKF6) (13) in OME but these models have not been characterised thoroughly 
and in some studies have resulted in poorly differentiated epithelium or epithelial layers of 
only 3-4 cells thick (24, 25). In this study we investigated whether FNB6 TERT-immortalised 
oral keratinocytes could be used to replace NOK in OME and whether their gene expression 
responses were similar to NOK OME upon stimulation with pro-inflammatory stimuli.   
 
The histological structure and expression of key markers of epithelial integrity, stratification, 
differentiation and keratinisation were similar between the normal oral mucosa and OME 
generated from NOK and FNB6 cells. Similar findings were observed in a recent study 
examining the histological similarities of 3D equivalent models based on TERT-immortalised 
gingival keratinocytes when compared to gingival tissue (26). However, there are key 
differences between these oral equivalent models the most important of which is the 
presence of a non-keratinised epithelium in FNB6 models compared to those based on 
immortalised gingival keratinocytes that are keratinised. Therefore, models based on TERT-
immortalised oral keratinocytes have the ability to retain their distinct keratinisation status 
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(non-keratinised, buccal for FNB6 and keratinised gingiva for immortalised gingival 
keratinocytes) and display a similar respective keratinisation phenotype to OME based on 
normal buccal or gingival keratinocytes despite all these models containing gingival 
fibroblasts in the connective tissue scaffold) that are important considerations for used of 
these OME.  OME created using the oral squamous cell carcinoma cell line H357 exhibited 
characteristics more consistent with the origin of these cells with proliferation in all levels of 
the epithelium, a lack of stratification and abnormal expression of differentiation markers. 
At times invasion of the underlying collagen matrix was observed; a characteristic that 
makes such 3D models more amenable to the study of tumorigenesis than normal mucosal 
physiology (8, 27).  
  
The human oral cavity harbours a range of micro-organisms that is continuously evolving 
and responding to environmental conditions. The interaction between these organisms and 
the host’s immune system is carefully regulated to prevent the development of disease 
pathology. The epithelium is the first line of defence against bacteria both physically and in 
triggering the immune response (28, 29). Oral keratinocytes and fibroblasts co-ordinate the 
initial innate immune response through the production of cytokines and chemokines that 
attract immune cells to the site of infection (28, 30). Previous reports suggest that 
fibroblasts play an important role in the epithelial inflammatory response (31). However, a 
minimal response to oral bacteria was noted in NOK OME compared to primary epithelial 
cell monolayers which the authors suggested was due to poor penetration of bacteria into 
the epithelial layer in a way that presumably soluble mediators circumvent (32). 
Furthermore, there is little change in cytokine production by 3D models exposed to P. 
gingivalis with and without fibroblasts (14). 
Page 19 of 37
Mary Ann Liebert, Inc.,140 Huguenot Street, New Rochelle, NY 10801
Tissue Engineering
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review ONLY/ Not for Distribution 19
  
We have shown that NOK-based and FNB6 OME respond to the pro-inflammatory stimulus 
of IL-1β and TNFα in a similar way and that this can consistently be monitored using CXCL8 
ELISA on the conditioned medium, CXCL8 and ICAM-1 qPCR and broader screening using 
gene array analysis. Others have shown that 3D models containing multiple cell types 
relevant to intestine respond to IL-1 by releasing CXCL8 and that anti-inflammatory 
interventions can be tested using such a model (33). Skin equivalents using immortalised 
keratinocytes have also been shown to respond to thermal injury by enhanced secretion of 
inflammatory cytokines including IL-6 and CXCL8, although generally the level of this 
response was less than models using primary keratinocytes (34).  
 
The response to E.coli LPS was much less obvious for all models than that initiated by 
cytokine stimulus. Others have reported a poor response of oral epithelial cells to LPS (35) 
that may relate to lack of expression of the relevant TLRs, CD14 or the culture conditions. 
TLR4 expression has been previously observed on NOK and immortalised oral keratinocytes 
by immunohistochemistry and PCR (36, 37). TLR4 expression was donor dependent for NOK 
and may explain the variation in gene expression observed in our whole genome 
transcription analysis in response to LPS stimulation between immortalised FNB6 and NOK. 
In addition, we found that OME comprised of oral cancer cells displayed increased CXCL8 
expression in response to LPS compared to OME comprised of NOK or immortalised oral 
keratinocytes that may be due to increased expression of TLR4 observed on OSCC cells 
compared to normal oral mucosa (38). It may be that by using whole bacteria or the LPS 
from oral species that a more appropriate response would be elicited. Sugiyama et al (2002) 
demonstrated that monolayers of gingival epithelial cells responded to surface components 
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of Porphyromonas gingivalis and Prevotella intermedia by increasing production of CXCL8, 
GCSF, GMCSF and ICAM-1 but that LPS from P. intermedia or E. coli did not (39). Others 
showed that live Streptococcus salivarius is capable of inducing IL-6, CXCL8 and TNFα in an 
oral mucosal model (40). More recently it has been suggested that the more complex nature 
of polymicrobial diseases such as periodontal disease may be better reflected by challenging 
oral mucosal models with multi-species biofilms (41, 42). Some cytokine responses in OME 
using oral cells have been significant (41) whilst others have been more modest (43, 44) and 
3D oral mucosal models generated using SV40 T-antigen transformed gingival epithelial cells 
responded to Aggegatibacter actinonomycetemocomitans LPS and that this effect is 
enhanced by the presence of fibroblasts (44).  
 
Array analysis revealed a similar inflammatory gene signature pathway for both NOK and 
FNB6 OME in response to the cytokines with more genes significantly up-regulated than 
down-regulated. Of the top 10 genes overexpressed between NOK and FNB6 OME most 
were predominately associated with leukocyte chemotaxis that would mediate 
inflammatory cell recruitment into the epithelium (CXCL5, CCL20, CXCL8, CXCL3). Pathway 
analysis revealed that common downstream mediators such as NFκB, which are known 
targets of IL-1β and TNFα, are influenced in a similar way between NOK and FNB6 models 
confirming that this is a suitable stimulus to produce a model of inflamed oral mucosa (45). 
What was apparent however was that different batches of NOK OME that showed variation 
in their response.  The response of FNB6-based OME was more consistent from batch to 
batch and as such a viable model of inflamed oral mucosa. 
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In conclusion, this study shows that OME based on immortalised FNB6 cells are able to 
mimic the native oral mucosa structure and replicate tissue responses to inflammatory 
mediators observed with NOK-based models and therefore provide a readily available 
alternative to NOK. 
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Table 1. Details of antibodies used for immunohistochemistry. 
Table 2. Top 10 genes up-regulated by NOK-OME upon stimulation with TNF-α and IL-1β.  
Table 3. Top 10 genes up-regulated by FNB6-OME upon stimulation with TNF-α and IL-1β.  
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Figure	legends	
	
Figure	1.	FNB6	OME	display	similar	characteristics	 to	human	oral	mucosa.	
OME	 were	 generated	 by	 culturing	 FNB6	 or	 H357	 cells	 on	 top	 of	 a	 fibroblast-
populated	 collagen	 scaffold	 and	 compared	 to	NOK-based	OME	and	human	 oral	
mucosa.	 Histological	 (H&E)	 and	 immunohistochemical	 analysis	 for	 ki67,	
cytokeratin	 13	 and	 14	 and	 E-cadherin	 were	 used	 to	 characterise	 the	 models.	
Representative	images	are	from	three	independent	experiments.	Scale	bar	=	100	
μm.	
	
Figure	2.	Gene	expression	of	CXCL8	and	ICAM-1	by	FNB6	OME	increases	in	
response	 to	 stimulation.	 FNB6,	 NOK	 or	 H357	 OME	 was	 stimulated	 with	 a	
combination	 of	 10	 ng/ml	 IL-1β	 and	 20	 ng/ml	 TNFα,	 100ng/ml	 E. coli LPS	
medium	as	control	for	24	h	and	gene	expression	for	CXCL8	and	ICAM-1	analysed	
by	 qPCR.	 Data	 are	 from	 at	 least	 3	 independent	 experiments	 performed	 in	
triplicate.	*	Indicates	significant	difference	(p<0.05)	from	control.		
	
Figure	3.	Protein	expression	of	CXCL8	by	FNB6	OME	increases	in	response	
to	 stimulation.	FNB6	 (A),	 NOK	 (B)	 or	 H357	 (C)	 OME	were	 stimulated	with	 a	
combination	 of	 10	 ng/ml	 IL-1β	 and	 20	 ng/ml	 TNFα,	 100	 ng/ml	 E. coli LPS	
medium	as	control	for	24	h	and	protein	expression	for	CXCL8	analysed	by	ELISA.	
Data	 are	 from	 at	 least	 3	 independent	 experiments	 performed	 in	 triplicate.	 *	
Indicates	significant	difference	(p<0.05)	from	control.		
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Figure	 4.	 Whole	 genome	 expression	 of	 FNB6	 and	 NOK	 OME.	 Heat	 map	
analysis	 of	microarray	 gene	 analysis	 of	 FNB6	 and	NOK	OME	 stimulated	with	a	
combination	 of	 10	 ng/ml	 IL-1β	 and	 20	 ng/ml	 TNFα,	 100	 ng/ml	 E. coli LPS	
medium	 as	 control	 for	 24	 h	 (up-regulated	 genes	 in	 green	 and	 down-regulated	
genes	 in	red;	A).	Principle	Component	Analysis	of	whole	genome	responses	 for	
cytokine,	LPS-treated	compared	to	medium	control	(B).	Data	are	from	at	least	3	
independent	experiments.	Array	data	show	genes	significantly	(p<0.05)	affected	
compared	to	control.		
	
Figure	5.	Activation	of	signal	transduction	pathways	is	similar	in	FNB6	and	
NOK	OME.	 	Signal	 transduction	 pathway	 data	 analysis	 (DAVID)	 from	 the	 gene	
data	 for	 FNB6	 OME	 show	 up-regulation	 for	 genes	 in	 the	 NFκB	 pathway	 (A).	
Principle	Component	Analysis	of	whole	genome	responses	for	FNB6	compared	to	
NOK	 OME	 showing	 batch-to-batch	 variability	 in	 gene	 responses	 between	 the	
models	(B).	
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2. Gene expression of CXCL8 and ICAM1 by FNB6 OME increases in response to stimulation. FNB6, 
NOK or H357 OME was stimulated with a combination of 10 ng/ml IL1β and 20 ng/ml TNFα, 100ng/ml E. 
coli LPS medium as control for 24 h and gene expression for CXCL8 and ICAM1 analysed by qPCR. Data are 
from at least 3 independent experiments performed in triplicate. * Indicates significant difference (p<0.05) 
from control.  
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Figure 3. Protein expression of CXCL8 by FNB6 OME increases in response to stimulation. FNB6 (A), NOK (B) 
or H357 (C) OME were stimulated with a combination of 10 ng/ml IL11β and 20 ng/ml TNFα, 100 ng/ml E. 
coli LPS medium as control for 24 h and protein expression for CXCL8 analysed by ELISA. Data are from at 
least 3 independent experiments performed in triplicate. * Indicates significant difference (p<0.05) from 
control.  
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Figure 4. Whole genome expression of FNB6 and NOK OME. Heat map analysis of microarray gene analysis 
of FNB6 and NOK OME stimulated with a combination of 10 ng/ml IL(1β and 20 ng/ml TNFα, 100 ng/ml E. 
coli LPS medium as control for 24 h (up(regulated genes in green and down(regulated genes in red; A). 
Principle Component Analysis of whole genome responses for cytokine, LPS(treated compared to medium 
control (B). Data are from at least 3 independent experiments. Array data show genes significantly (p<0.05) 
affected compared to control.  
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Figure 5. Activation of signal transduction pathways is similar in FNB6 and NOK OME.  Signal transduction 
pathway data analysis (DAVID) from the gene data for FNB6 OME show up'regulation for genes in the NFκB 
pathway (A). Principle Component Analysis of whole genome responses for FNB6 compared to NOK OME 
showing batch'to'batch variability in gene responses between the models (B).  
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Table 1. Details of antibodies used for immunohistochemistry. 
Name Clone Company Working 
concentration (μg/ml) 
Ck13 AE8 ThermoScientific 1.0 
Ck14 LL002 ThermoScientific 0.3 
Ki67 MIB-1 DAKO 1.0 
E-cadherin EP700Y Abcam 0.5 
IgG Control 11711 R&D Systems 1.0 
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Table 2. Top 10 genes up-regulated by NOK-OME upon stimulation with TNF-α and IL-1β.  
 
Gene Fold-Change p-value 
TNFAIP6 14.07 0.0038 
CXCL10 13.51 0.0198 
CXCL11 9.43 0.0463 
VNN1 6.31 0.0029 
CCL20 6.20 0.0001 
IL36G 6.02 0.0080 
OLR1 5.32 0.0188 
CXCL8 5.14 0.0039 
S100A7A 5.13 0.0187 
IL6 4.86 0.0005 
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Table 3. Top 10 genes up-regulated by FNB6-OME upon stimulation with TNF-α and IL-1β.  
Gene Fold-Change p-value 
IL6 7.99 0.0011 
CXCL8 7.11 0.0001 
PTX3 5.87 0.0125 
PTGS2 4.86 0.0295 
CXCL3 4.75 0.0177 
CCL20 4.65 0.0090 
CXCL5 4.23 0.0007 
IRAK2 3.81 0.0177 
IL36G 3.81 0.0254 
TNFAIP3 3.58 0.0153 
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